Pharma Focus Asia
KP - Choose our fully recyclable blister films

Susvimo™, Breakthrough Therapy Discovered for Wet Age-Related Macular Degeneration (nAMD)

Roche discovered breakthrough therapy Susvimo™ (ranibizumab injection) for the treatment of people with neovascular or ‘wet’ age-related macular degeneration (nAMD).

Susvimoearlier known as port delivery system with ranibizumab is the first and only alternative treatment in 15 years which provides standard-of-care eye injections which requires often in a month.

Susvimo is delivered to eye through refillable implant. The implant is inserted into the eye during a one-time, outpatient procedure and refilled every six months. It helps people with nAMDto maintain their vision as few as two treatments per year. It provides as an alternative to anti-VEGF eye injections by delivering susvimocontinuously.

With the advancements in treatment, Susvimo plays as a new treatment option for patients with wet AMD.

U.S. Food and Drug Administration (FDA) approves Susvimo™, as a first-of-its-kind therapeutic approach for neovascular or ‘wet’ age-related macular degeneration (nAMD).

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024